Clinical trials have examined the efficacy of a MET inhibitor in combination with antiangiogenic therapy in patients with triple-negative BC and, interestingly, the addition of onartuzumab to either paclitaxel and bevacizumab or paclitaxel alone did not improve PFS or OS compared with paclitaxel and bevacizumab; furthermore, the efficacy in the MET-positive and MET-negative subgroups was similar [23]. The gene discussed is MET; the disease is breast cancer.